Pharmacogenetic considerations for migraine therapies

References

• Fernandez F, Colson NJ, Griffiths LR. Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy. Pharmacogenomics. 2007;8(6):609–622.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci. 2006;27(8): 410–415. Epub 2006 Jul 3.
   PubMed Web of Science ®Google Scholar
• The international classification of headache disorders 3rd edition. [Cited 2018 July 1]. Available from: https://www.ichd-3.org/1-migraine/
   Google Scholar
• Cui Y, Kataoka Y, Watanabe Y. Role of cortical spreading depression in the pathophysiology of migraine. Neurosci Bull. 2014;30(5):812–822.
   PubMed Web of Science ®Google Scholar
• Montagna P, Pierangeli G, Cevoli S, et al. Pharmacogenetics of headache treatment. Neurol Sci. 2005;26 Suppl 2:s143–s147.
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Moskowitz MA. The pathophysiology of migraine: year 2005. J Headache Pain. 2005;6(3):105–111.
   PubMedGoogle Scholar
• Goadsby PJ. Migraine pathophysiology. Headache. 2005;45 Suppl 1:S14–24.
   PubMed Web of Science ®Google Scholar
• May A. A review of diagnostic and functional imaging in headache. J Headache Pain. 2006;7(4):174–184.
   PubMedGoogle Scholar
• Martínez E, Moreno R, López-Mesonero L, et al. Familial hemiplegic migraine with severe attacks: a new report with ATP1A2 mutation. Case Rep Neurol Med. 2016;2016:3464285.
   PubMedGoogle Scholar
• Koenderink JB, Zifarelli G, Qiu LY, et al. Na,K-ATPase mutations in familial hemiplegic migraine lead to functional inactivation. Biochim Biophys Acta. 2005;1669(1):61–68.
   PubMed Web of Science ®Google Scholar
• Montagna P. The physiopathology of migraine: the contribution of genetics. Neurol Sci. 2004;25 Suppl 3:S93–S96.
   PubMed Web of Science ®Google Scholar
• Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics. 2007;4(2):274–284.
   PubMed Web of Science ®Google Scholar
• Van Den Maagdenberg AM, Terwindt GM, Haan J, et al. Genetics of headaches. Handb Clin Neurol. 2010;97:85–97.
   PubMedGoogle Scholar
• Tfelt-Hansen P, Brøsen K. Pharmacogenomics and migraine: possible implications. J. Headache Pain. 2008;9(1):13–18.
   PubMed Web of Science ®Google Scholar
• Morris-Rosendahl DJ, Fiebich BL. The future of genetic testing for drug response. Dialogues Clin Neurosci. 2004;6(1):27–37.
   PubMedGoogle Scholar
• Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. Aaps J. 2018;20(1):4.
   Web of Science ®Google Scholar
• Laura Dean. National Center for Biotechnology Information: celecoxib Therapy and CYP2C9 Genotype. Bethesda (MD); 2012. [Cited 2018 Jul 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK379478/
   Google Scholar
• Bertilsson L, Dahl ML, Dalén P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. J Clin Pharmacol. 2002;53(2):111–122.
   Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981.
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh GN. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Engl J Med. 1999;340(24):1888–1899.
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289(2):735–741.
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Arroyo MT, et al. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. A Best Pract Res Clin Gastroenterol. 2010;24(2):121–132.
   PubMed Web of Science ®Google Scholar
• Papetti L, Spalice A, Nicita F, et al. Migraine treatment in developmental age: guidelines update. J Headache Pain. 2010;11(3):267–276.
   PubMed Web of Science ®Google Scholar
• Fowler TO, Durham CO, Planton J, et al. Use of nonsteroidal anti-inflammatory drugs in the older adult. Edlund BJ.J Am Assoc Nurse Pract. 2014;26(8):414–423.
   PubMed Web of Science ®Google Scholar
• Kuehl GE, Bigler J, Potter JD, et al. Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos. 2006;34(2):199–202.
   PubMed Web of Science ®Google Scholar
• De Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert’s syndrome. Gastroenterology. 1992;102(2):577–586.
   PubMed Web of Science ®Google Scholar
• Gentile G, Chiossi L, Lionetto L, et al. Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014;15(11):1539–1550.
   PubMed Web of Science ®Google Scholar
• Sánchez-Diz P, Estany-Gestal A, Aguirre C, et al. Prevalence of CYP2C9 polymorphisms in the south of Europe. Pharmacogenomics J. 2009;9(5):306–310.
   PubMed Web of Science ®Google Scholar
• Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54(10):1257–1270.
   PubMed Web of Science ®Google Scholar
• Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–1153.
   PubMed Web of Science ®Google Scholar
• Agúndez JA, García-Martín E, Martínez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine. Expert Opin Drug Metab Toxicol. 2009;5(6):607–620.
   PubMed Web of Science ®Google Scholar
• Elena García‐Martín MD, Carmen Martínez MD, Beatriz Tabarés MD, et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Pharmacogenetics and genomics. Clin Pharmacol Ther. 2004;76(2):119–127.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001;51(5):437–441.
   PubMed Web of Science ®Google Scholar
• Gentile G, Borro M, Lala N, et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. 2010;11(5):431–435.
   PubMed Web of Science ®Google Scholar
• Schürks M, Kurth T, Stude P, et al. G protein beta3 polymorphism and triptan response in cluster headache. Pharmacol Ther. 2007;82(4):396–401.
   Web of Science ®Google Scholar
• Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk ofinconsistent response to triptans in migraine patients. Eur J Pharmacol. 2010;641(2–3):82–87.
   PubMed Web of Science ®Google Scholar
• Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14(1):27–35.
   PubMed Web of Science ®Google Scholar
• Dusitanond P, Young WB. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem. 2009;9(1):63–70.
   PubMedGoogle Scholar
• Fernandez F, Lea RA, Colson NJ, et al. Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci. 2006;251(1–2):118–123.
   PubMed Web of Science ®Google Scholar
• Antonaci F, Ghiotto N, Wu S, et al. Recent advances in migraine therapy. Springerplus. 2016 17;5:637.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey SJD. Pharmacokinetic - pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition DG. ClinPharmacokinet. 2000;38(1):41–57.
   PubMed Web of Science ®Google Scholar
• Kellerman D, Kori S, Forst A, et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Cephalalgia. 2012;32(2):150–158.
   PubMed Web of Science ®Google Scholar
• Freitag FG, Shumate D. Current and investigational drugs for the prevention of migraine in adults and children. CNS Drugs. 2014;28(10):921–927.
   PubMed Web of Science ®Google Scholar
• Helfand M, Peterson K, Christensen V, et al. Drug Class Review: beta Adrenergic Blockers: final Report Update 4. Portland (OR): Oregon Health & Science University; 2009 Jul.
   Google Scholar
• Kabbouche MA, Gilman DK. Management of migraine in adolescents. Neuropsychiatr Dis Treat. 2008;4(3):535–548.
   PubMedGoogle Scholar
• Gooriah R, Nimeri R, Ahmed F. Pain Research and Treatment: evidence-Based Treatments for Adults with Migraine Pain Research and Treatment. Hull, UK: Department of Neurology, Hull Royal Infirmary; 2015.
   Google Scholar
• Cavallari LH, Mason DL. Cardiovascular pharmacogenomics – implications for patients with chronic kidney disease. A Adv Chronic Kidney Dis. 2016;23(2):82–90.
   PubMed Web of Science ®Google Scholar
• Xu J, Boström AE, Saeed M, et al. A genetic variant in the catechol-O-methyl transferase (COMT) gene is related to age-dependent differences in the therapeutic effect of calcium-channel blockers. Medicine (Baltimore). 2017;96(30):e7029.
   PubMed Web of Science ®Google Scholar
• Silberstein.Review SD. Neurological Disorder: preventive Treatment of Migraine. Philadelphia, PA: Department of Neurology, Jefferson Medical College of Thomas Jefferson University; 2005.
   Google Scholar
• Park JJ, Park KW, Kang J, et al. CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel. Circ J. 2013;77(5):1289–1296.
   PubMed Web of Science ®Google Scholar
• Lance JW, Curran DA. Treatment of chronic tension headache. Lancet. 1964;1:1236–1239.
   PubMed Web of Science ®Google Scholar
• Xu XM, Liu Y, Dong MX. et al. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore). 2017;96(22):e6989.
   PubMed Web of Science ®Google Scholar
• Khalid MM, Waseem M. StatPearls: toxicity, Tricyclic AntidepressanT. Treasure Island (FL): StatPearls Publishing; 2018.
   Google Scholar
• Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–408.
   PubMed Web of Science ®Google Scholar
• Shahien R, Beiruti KJ. Preventive agents for migraine: focus on the antiepileptic drugs. Cent Nerv Syst Dis. 2012;4:37–49.
   PubMedGoogle Scholar
• O’Brien HL, Kabbouche MA, Hershey AD. Treatment of acute migraine in the pediatric population. Curr Treat Options Neurol. 2010;12(3):178–185.
   PubMed Web of Science ®Google Scholar
• Toldo I, De Carlo D, Bolzonella B, et al. The pharmacological treatment of migraine in children and adolescents: an overview. Expert Rev Neurother. 2012;12(9):1133–1142.
   PubMed Web of Science ®Google Scholar
• DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37 Suppl 2:25–42.
   PubMedGoogle Scholar
• Kulkarni C, Chaudhuri UR, Jagathesan A. Bilateral acute angle-closure glaucoma following treatment with topiramate for headache. Neurol Ther. 2013;2(1–2):57–62.
   PubMedGoogle Scholar
• Pomes LM, Gentile G, Simmaco M, et al. Tailoring treatment in polymorbid migraine patients through personalized medicine. CNS Drugs. 2018;32:559–565.
   Web of Science ®Google Scholar